🔗 Share this article WHO Issues Alert Over Acute Shortage of Weight-Loss Injections Less than one in 10 people who could benefit from weight-loss injections such as Wegovy are able to get them, caution the World Health Organization as it issues its initial advice on the medications. With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is urging more widespread and fairer availability to GLP-1 medication. According to projections, more than two billion could be obese by 2030 if no action is taken. "The new guidelines acknowledges that excess weight is a lifelong illness that can be treated with thorough and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and supply-chain constraints are key hurdles to universal availability to the injections that can help people shift significant body mass, explains the body. GLP-1 Therapy Scarcity Despite the current best projected outlook, the manufacturing of GLP-1 therapies could only cover approximately 100 million people – less than 10% of eligible patients, according to the health organization. The advice urges governments and firms to expand access, through measures such as patent sharing. The intellectual property rights on a key compound – the primary ingredient of a leading brand – is set to lapse in multiple nations in 2026. How Weight-Loss Jabs Function These medications imitate a body's own hormone to delay gastric emptying, curb appetite and boost satiety so users consume fewer calories. People commonly begin shedding pounds within a few weeks of beginning the once-weekly jabs. Evidence points to users may see weight return within a year of halting the drug, when their normal hunger come back. Being overweight or obese raises your likelihood for experiencing medical conditions, such as type 2 diabetes, heart disease, stroke, and certain cancers. Obesity impacts individuals in every country and was responsible for over three and a half million fatalities worldwide in 2024, according to the WHO.
Less than one in 10 people who could benefit from weight-loss injections such as Wegovy are able to get them, caution the World Health Organization as it issues its initial advice on the medications. With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is urging more widespread and fairer availability to GLP-1 medication. According to projections, more than two billion could be obese by 2030 if no action is taken. "The new guidelines acknowledges that excess weight is a lifelong illness that can be treated with thorough and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and supply-chain constraints are key hurdles to universal availability to the injections that can help people shift significant body mass, explains the body. GLP-1 Therapy Scarcity Despite the current best projected outlook, the manufacturing of GLP-1 therapies could only cover approximately 100 million people – less than 10% of eligible patients, according to the health organization. The advice urges governments and firms to expand access, through measures such as patent sharing. The intellectual property rights on a key compound – the primary ingredient of a leading brand – is set to lapse in multiple nations in 2026. How Weight-Loss Jabs Function These medications imitate a body's own hormone to delay gastric emptying, curb appetite and boost satiety so users consume fewer calories. People commonly begin shedding pounds within a few weeks of beginning the once-weekly jabs. Evidence points to users may see weight return within a year of halting the drug, when their normal hunger come back. Being overweight or obese raises your likelihood for experiencing medical conditions, such as type 2 diabetes, heart disease, stroke, and certain cancers. Obesity impacts individuals in every country and was responsible for over three and a half million fatalities worldwide in 2024, according to the WHO.